ReviewClinical microbiology reviews2026
Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness.
Review in Clinical microbiology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Performance comparison of large language models for medication counseling in people living with HIV.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
SUMMARYThis review summarizes potential drug-drug interactions (DDIs) between long-acting antiretrovirals (LAAs) and opioids, focusing on pharmacodynamics (PD), pharmacokinetics (PK), and side effects related to absorption, distribution, metabolism, and excretion (ADME). It also covers dysregulation in epigenetics and in the immune system. A comprehensive literature review was performed using PubMed and Google Scholar, along with data from the Liverpool HIV Drug Interactions Database, to evaluate pharmacokinetic interactions between LAA drugs, such as cabotegravir, rilpivirine, lenacapavir, and dapivirine, with opioids used in clinical settings, including morphine, tramadol, oxycodone, and codeine; medications for opioid use disorder (MOUD), such as methadone and buprenorphine; and the illicit opioids, including fentanyl and heroin. The review highlights key factors increasing DDI risk and discusses clinical considerations for managing preexposure prophylaxis (PrEP) or antiretroviral therapy (ART) in persons who use opioids. Lastly, it proposes research strategies for studying DDIs, including the use of animal models, physiologically based pharmacokinetic (PBPK) models, and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.